In January 2026, Amaero Ltd. updated its earnings guidance for fiscal 2026, lifting expected revenue to A$18,000,000–A$20,000,000, representing a very large increase over fiscal 2025. This sharp ...

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®Phase 3 trial of ...